Abstract
The increasing use of intravenous immunoglobulin-G preparations (IVIg) calls for evaluation of the requirements for quality and freedom from infection. The WHO Requirements dating from 1982 have been surpassed by the majority of IVIg preparations. Three methods are used for ensuring safety from infection: the restrictive choice of donor, the precise introductory screening of every individual blood or plasma donation, and the additional active virus inactivation procedures that surpass the virus elimination of, for example, the Cohn-fractionation method. Although it is highly improbable that IVIg can transfer infections, this possibility cannot be completely ruled out even when all the GMP (good manufacturing practice) rules are observed most carefully. Increased safety from infection would be provided if blood and plasma donations were obtained nationally from unpaid voluntary donors and if an additional active viral inactivation procedure was introduced.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Berkman S. A., Lee M. L., Gale R. P. Clinical uses of intravenous immunoglobulins. Ann Intern Med. 1990 Feb 15;112(4):278–292. doi: 10.7326/0003-4819-112-4-278. [DOI] [PubMed] [Google Scholar]
- Berkman S. A., Lee M. L., Gale R. P. Clinical uses of intravenous immunoglobulins. Semin Hematol. 1988 Apr;25(2):140–158. [PubMed] [Google Scholar]
- Morgenthaler J. J. Effect of ethanol on viruses. Curr Stud Hematol Blood Transfus. 1989;(56):109–121. doi: 10.1159/000416561. [DOI] [PubMed] [Google Scholar]
- Prince A. M., Horowitz B., Horowitz M. S., Zang E. The development of virus-free labile blood derivatives--a review. Eur J Epidemiol. 1987 Jun;3(2):103–118. doi: 10.1007/BF00239746. [DOI] [PubMed] [Google Scholar]